(Total Views: 329)
Posted On: 11/21/2019 8:07:40 AM
Post# of 153916
Yes, it's another huge advantage of leronlimab over HAART.
However, the PR lacks the details necessary to judge how good the results were. If we had a point of reference, we could compare to Viking and Madrigal for instance.
It's not like that this PR will automatically make us a 1b company and let us have a figantic deal, which NP sometimes suggested.
However, the PR lacks the details necessary to judge how good the results were. If we had a point of reference, we could compare to Viking and Madrigal for instance.
It's not like that this PR will automatically make us a 1b company and let us have a figantic deal, which NP sometimes suggested.
(1)
(0)
